A five year follow-up study of the use of clozapine in community practice

References

• Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for treatment resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45: 789–796
   PubMed Web of Science ®Google Scholar
• Wahlbeck K., Cheine M., Essali M A. Clozapine versus typical neuroleptic medication for schizophrenia. The Cochrane Library, [Cited 22 November 2001.] Available from URL: http://gateway2.ovid.com/ovidweb.cgi
   Google Scholar
• Barnes T R.E, Joyce E M. Antipsychotic drug treatment: recent advances. Current Opinion in Psychiatry 2001; 14: 25–37
   Web of Science ®Google Scholar
• Chakos M., Lieberman J., Hoffman E., Bradfield D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and metaanalysis of randomised trials. American Journal of Psychiatry 2001; 158: 518–526
   PubMed Web of Science ®Google Scholar
• Aitcheson K., Kerwin R W. Cost-effectiveness of clozapine. A UK clinic-based study. British Journal of Psychiatry 1997; 171: 125–130
   PubMed Web of Science ®Google Scholar
• Dickson R A, Dalby J T, Williams R., Warden S J. Hospital days in clozapine- treated patients. Canadian Journal of Psychiatry 1998; 43: 945–948
   PubMed Web of Science ®Google Scholar
• Drew L R.H, Hodgson D M, Griffiths K M. Clozapine in community practice: a 3-year follow-up study in the Australian Capital Territory. Australian and New Zealand Journal of Psychiatry 1999; 33: 667–675
   PubMed Web of Science ®Google Scholar
• Honer W G, MacEwan G W, Kopala L., et al. A clinical study of clozapine treatment and predictors of response in a Canadian sample. Canadian Journal of Psychiatry 1995; 40: 208–211
   PubMed Web of Science ®Google Scholar
• Pollack S., Woerner M G, Howard A., et al. Clozapine reduces rehospitalisation among schizophrenia patients. Psychopharmacology Bulletin 1998; 34: 89–92
   PubMedGoogle Scholar
• Erlandsen C. Clozapine for schizophrenia. Nordic Journal of Psychiatry 2000; 54: 143–148
   Web of Science ®Google Scholar
• Killian J G, Kristin K., Lawrence C., Celermajer D S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–1845
   PubMed Web of Science ®Google Scholar
• Lieberman J A. Maximising clozapine therapy: managing side-effects. Journal of Clinical Psychiatry 1998; 59(Suppl. 3)38–43
   PubMed Web of Science ®Google Scholar
• Young C R, Bowers M B, Jr, Mazure C M. Management of the adverse effects of clozapine. Schizophrenia Bulletin 1998; 24: 381–390
   PubMed Web of Science ®Google Scholar
• Singh B., Hawthorne G., Vos T. The role of economic evaluation in mental health care. Australian and New Zealand Journal of Psychiatry 2001; 35: 104–117
   PubMed Web of Science ®Google Scholar
• Revicki D A. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine related studies. Journal of Clinical Psychiatry 1999; 60((Suppl. 1))7–11
   PubMed Web of Science ®Google Scholar
• Glazer W M, Bryan M., Johnstone B M. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry 1997; 58(Suppl. 10)50–54
   PubMed Web of Science ®Google Scholar
• Maynard A., Bloor K. Building castles on sands or quicksands?. British Journal of Psychiatry 1998; 173((Suppl. 36))12–18
   Web of Science ®Google Scholar
• Taylor D M. Establishing cost-effectiveness of antipsychotic drugs. British Journal of Psychiatry 1997; 171: 486
   PubMed Web of Science ®Google Scholar
• Overall J E, Gorham D R. The Brief Psychiatric Ratings Scale. Psychological Reports 1962; 10: 799–872
   Web of Science ®Google Scholar
• Rosen A., Hadzi-Pavlovic D., Parker G. The Life Skills Profile: a measure assessing function and disability in schizophrenia. Schizophrenia Bulletin 1989; 15: 325–337
   PubMed Web of Science ®Google Scholar
• Keck P E, Strakowski S M, McElroy S L. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Journal of Clinical Psychiatry 2000; 61((Suppl. 3))4–9
   PubMed Web of Science ®Google Scholar
• Meltzer H Y. Treatment of suicidality in schizophrenia. The clinical science of suicide prevention. Annals of the New York Academy of Sciences 2001; 932: 44–60
   PubMed Web of Science ®Google Scholar
• Reid W H, Mason M., Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatric Services 1998; 49: 1029–1033
   PubMed Web of Science ®Google Scholar
• Sernyak M J, Desai R., Stolar M., Rosenheck R. Impact of clozapine in completed suicide. American Journal of Psychiatry 2001; 158: 931–937
   PubMed Web of Science ®Google Scholar
• Stahl S M. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Journal of Clinical Psychiatry 1999; 60((Suppl. 10))31–41
   PubMed Web of Science ®Google Scholar